Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-02-05T09:26:29+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

Analyst coverage: Updated NDF Research note

NDF Research have updated their coverage note titled "Dimerix - DMX-200's credibility increases" The report is available here.

ASX: Chief Medical Officer appointment and trial update

Dimerix is pleased to announce the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO), and has [...]

ASX: Dimerix on Channel 7 News

Dimerix's DMX-200 clinical program has been featured on Channel 7 News. Full details are available here. The video is available on [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation